ARCH:TSXV ACHFF:OTC
  • Home
  • About usOur story, our approach
  • Our Science Pipeline, research & publications
    • Our Key Platforms
      • MetaBlok™Treating, organ injury caused by inflammation
      • AB569Treatment for Respiratory Pseudomonas aeruginosa Infections
      • BORGPeptide Solid Surface Interface
      • MetaMx™Brain Tumor Initiating Cell Targeting
    • Our PublicationsPeer-reviewed scientific publications
      • AB569
      • Brain Tumor Stem Cell Targeting
      • BORG Peptide Solid Surface Interface
      • Treatments for Inflammation
  • Our Team Management & lead scientists
    • Our ManagementGovernance, Executive, Board of Directors and Advisors
    • Our Principal ScientistsLearn about the scientists behind our technologies
      • MetaBlok™ and MetaMx™
      • AB569 & Respiratory Pseudomonas
      • BORG Peptide
      • Treatments for Inflammation
  • Investor Hub Investor relations, fundamentals
    • Fundamentals
      • Press Releases
      • Investor Information
      • Stock Performance
    • Reports and Filings
      • Management Discussion and Analysis
      • Annual and Quarterly Reports
      • Proxies and Information Circulars
      • Material Change Documents
      • Other SEDAR Filings
  • Contact Us

MetaMx™

Brain Tumor Initiating Cell Targeting

MetaMx™ is composed of novel, synthetic peptides that target and attach to BTICs and invasive glioma cells, for the purpose of imaging, diagnosis and developing targeted therapies to improve patient outcomes and survival rates among glioblastoma patients.

Read more ...

MetaBlok™

Metablok (LSALT peptide) is our lead drug candidate for treating inflammation in the lungs, liver and kidneys. 

Arch believes Metablok has the potential to deliver a major breakthrough in the treatment of diseases where inflammation plays a major role. In August 2019, a scientific team led by Arch scientists Dr. Donna Senger and Dr. Stephen Robbins published a paper in the journal Cell  describing a novel mechanism of action for organ inflammation. In the publication, the enzyme dipeptidase-1 was identified as a major neutrophil (white blood cell) adhesion receptor on the lung, liver and kidney endothelium. In the same publication, dipeptidase-1 was shown to be the target of Metablok.

Arch is pursuing clinical development of Metablok to treat acute injury in the lungs, kidneys and liver caused by inflammation.

Arch is currently conducting a Phase II Trial to investigate Metablok’s efficacy in the prevention of multiple organ injuries in patients with COVID-19. Arch has announced that patient dosing in the United States and Turkey has begun. The trial is designed to target the prevention of acute lung injury, acute kidney injury and other complications caused by inflammation in hospitalized patients with moderate to severe cases of COVID-19. 

The Phase II trial is an international, multicenter, randomized, double-blind, placebo-controlled, proof of concept study of LSALT peptide (Metablok) as a treatment to prevent organ inflammation known to trigger acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI) in patients infected with SARS-CoV-2 (COVID-19).

In the worst cases of COVID-19 infection, fatalities are often linked to severe acute lung inflammation and subsequent respiratory failure, or acute kidney injury and renal failure.

In March 2020, Arch announced that Metablok successfully met the primary endpoints of safety and tolerability in a Phase I Human Trial involving 52 healthy, normal volunteers. The placebo controlled, double blind study was conducted in Australia.

Read more ...

AB569

AB569: Treatment for Drug Resistant Bacterial Infections

AB569 is a new drug candidate for treating antibiotic resistant bacterial infections, primarily in the lungs. It also has potential to be modified for use in other indications, including adaptation as a topical cream for bacterial skin infections.

AB569 has a mechanism of action that differs from the mechanism of action of antibiotics. AB569 has orphan drug status from the U.S. FDA for the treatment of Pseudomonas aeruginosa infections in the respiratory tracts of patients with cystic fibrosis. AB569 has orphan medicinal product designation from the European Medicines Agency for the treatment of cystic fibrosis.

Read more ...

BORG

Peptide Solid Surface Interface

Arch has developed a group of novel synthetic peptides and peptide conjugates that employ a novel chemistry (non-toxic, and environmentally friendly process) to react with solid surfaces such as metals, and plastics to generate new materials that display new surface properties.

Read more ...

Recent News

March 4th 2021

ARCH Scientist Publishes Paper Showing Pre-Clinical Efficacy of AB569 in Eradicating Multi-Drug Resistant Pathogens Acinetobacter baumannii and Acinetobacter spp

Read More
February 26th 2021

Peter Lougheed Centre Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients

Read More
Arch Biopartners
  • Home
  • About us
  • Our Science
    • Our Key Platforms
    • Our Publications
  • Our Team
    • Our Management
    • Our Principal Scientists
  • Investor Hub
    • Fundamentals
    • Reports and Filings
  • Contact Us
Contact us
+1 647 428 7031
info@archbiopartners.com
Mailing Address
27 St. Clair Ave East
P.O. Box 305
Toronto, Ontario
Canada M4T 2M5
Copyright Arch BioPartners 2020. All Rights Reserved. Legal notices.
PAGE TOP | TYPE SIZE | | RESET
Reports and Filings
  • Home
  • About us
  • Our Science
    • Our Key Platforms
      • MetaBlok™
      • AB569
      • BORG
      • MetaMx™
    • Our Publications
      • AB569
      • Brain Tumor Stem Cell Targeting
      • BORG Peptide Solid Surface Interface
      • Treatments for Inflammation
  • Our Team
    • Our Management
    • Our Principal Scientists
      • MetaBlok™ and MetaMx™
      • AB569 & Respiratory Pseudomonas
      • BORG Peptide
      • Treatments for Inflammation
  • Investor Hub
    • Fundamentals
      • Press Releases
      • Investor Information
      • Stock Performance
    • Reports and Filings
      • Management Discussion and Analysis
      • Annual and Quarterly Reports
      • Proxies and Information Circulars
      • Material Change Documents
      • Other SEDAR Filings
  • Contact Us